Logo Logo
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Anzahl der Publikationen: 3

Zeitschriftenartikel

Behr, Jürgen ORCID logoORCID: https://orcid.org/0000-0002-9151-4829; Nathan, Steven D. ORCID logoORCID: https://orcid.org/0000-0002-6270-1617; Costabel, Ulrich ORCID logoORCID: https://orcid.org/0000-0003-2804-9511; Albera, Carlo ORCID logoORCID: https://orcid.org/0000-0002-0334-869X; Wuyts, Wim A.; Glassberg, Marilyn K. ORCID logoORCID: https://orcid.org/0000-0003-1990-6614; Haller, Harold; Alvaro, Giuseppe; Gilberg, Frank; Samara, Katerina und Lancaster, Lisa (2023): Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies. In: Advances in Therapy, Bd. 40, Nr. 9: S. 3937-3955 [PDF, 840kB]

Behr, Jürgen; Nathan, Steven D.; Wuyts, Wim A.; Bishop, Nesrin Mogulkoc; Bouros, Demosthenes E.; Antoniou, Katerina; Guiot, Julien; Kramer, Mordechai R.; Kirchgaessler, Klaus-Uwe; Bengus, Monica; Gilberg, Frank; Perjesi, Andras; Harari, Sergio und Wells, Athol U. (2021): Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. In: Lancet Respiratory Medicine, Bd. 9, Nr. 1: S. 85-95

Behr, Jürgen; Nathan, Steven D.; Harari, Sergio; Wuyts, Wim; Kirchgaessler, Klaus-Uwe; Bengus, Monica; Gilberg, Frank und Wells, Athol U. (2018): Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. In: Respiratory Medicine, Bd. 138: S. 13-20

Diese Liste wurde am Sat Mar 8 20:25:39 2025 CET erstellt.